Literature DB >> 24754532

Clinical considerations for an effective medical therapy in Wilson's disease.

Karl Heinz Weiss1, Wolfgang Stremmel.   

Abstract

Wilson's disease is an autosomal recessively inherited copper overload disorder that leads to hepatic and/or neurologic symptoms. More than a century after the first description of Wilson's disease, the available medical treatment options have not been standardized. The efficacy of the commonly used drugs is satisfactory for hepatic disease, but disappointing in the neurologic patients, including the risk of neurologic deterioration after the initiation of chelation therapy. An approach to overcome this problem is the careful and systematic assessment of biochemical response patterns and the quantitative monitoring of symptoms using validated rating scales. Standardized dosage strategies that address changes in copper pools might improve adherence and reduce side effects. Such an approach may reduce long-term morbidity. In this paper, we discuss considerations for an effective medical treatment and requirements for future studies in Wilson's disease.
© 2014 New York Academy of Sciences.

Entities:  

Keywords:  ATP7B; TTM; Wilson's disease; d-penicilamine; trientine

Mesh:

Substances:

Year:  2014        PMID: 24754532     DOI: 10.1111/nyas.12437

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

Review 1.  Current anti-copper therapies in management of Wilson disease.

Authors:  Isabelle Mohr; Karl Heinz Weiss
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Wilson disease-treatment perspectives.

Authors:  Tomasz Litwin; Karolina Dzieżyc; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

3.  Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.

Authors:  Jessica Seessle; Daniel Nils Gotthardt; Mark Schäfer; Annina Gohdes; Jan Pfeiffenberger; Peter Ferenci; Wolfgang Stremmel; Karl Heinz Weiss
Journal:  J Inherit Metab Dis       Date:  2015-06-12       Impact factor: 4.982

4.  Methanobactin reverses acute liver failure in a rat model of Wilson disease.

Authors:  Josef Lichtmannegger; Christin Leitzinger; Ralf Wimmer; Sabine Schmitt; Sabine Schulz; Yaschar Kabiri; Carola Eberhagen; Tamara Rieder; Dirk Janik; Frauke Neff; Beate K Straub; Peter Schirmacher; Alan A DiSpirito; Nathan Bandow; Bipin S Baral; Andrew Flatley; Elisabeth Kremmer; Gerald Denk; Florian P Reiter; Simon Hohenester; Friedericke Eckardt-Schupp; Norbert A Dencher; Jerzy Adamski; Vanessa Sauer; Christoph Niemietz; Hartmut H J Schmidt; Uta Merle; Daniel Nils Gotthardt; Guido Kroemer; Karl Heinz Weiss; Hans Zischka
Journal:  J Clin Invest       Date:  2016-06-20       Impact factor: 14.808

5.  Pregnancy and Wilson disease: management and outcome of mother and newborns-experiences of a perinatal centre.

Authors:  Ulrike Reuner; Juergen Dinger
Journal:  Ann Transl Med       Date:  2019-04

6.  Disappearance of Clinical and Imaging Manifestations in Wilson's Disease with Ammonium Tetrathiomolybdate and Zinc.

Authors:  Ignacio J Posada; Ana Ramos
Journal:  Mov Disord Clin Pract       Date:  2021-11-10

7.  Pearls & Oy-sters: Challenges and Controversies in Wilson Disease.

Authors:  Marta Ruiz-Lopez; Ana Moreno Estébanez; Beatriz Tijero; Tamara Fernandez; Alba Rebollo-Perez; Iñigo Gabilondo; Nuria Lopez-Osle; Leticia Ceberio-Hualde; Juan Jose Zarranz; Juan Carlos Gomez-Esteban
Journal:  Neurology       Date:  2022-06-13       Impact factor: 11.800

8.  Renal impairment in different phenotypes of Wilson disease.

Authors:  Honghao Wang; Zhihua Zhou; Jiyuan Hu; Yongzhu Han; Xun Wang; Nan Cheng; Yunfan Wu; Renmin Yang
Journal:  Neurol Sci       Date:  2015-07-29       Impact factor: 3.307

9.  The steady state pharmacokinetics of trientine in Wilson disease patients.

Authors:  Jan Pfeiffenberger; Carlot Kruse; Peter Mutch; Andrew Harker; Karl Heinz Weiss
Journal:  Eur J Clin Pharmacol       Date:  2018-02-07       Impact factor: 2.953

Review 10.  Current Drug Managements of Wilson's Disease: From West to East.

Authors:  Wen-Jie Li; Chen Chen; Zhi-Fei You; Ren-Min Yang; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.